Biovail at outperform by RBC

RBC Capital Markets analyst Douglas Miehm rated Biovail Corp. at outperform, above average risk, ahead of the company's release of second-quarter 2006 financial results. The analyst is forecasting earnings per share of $0.43 for the period, compared to the company's guidance of $0.40 to $0.50. Strong Wellbutrin and generic revenue may offset Ultram weakness, according to the analyst. The results are likely to be overshadowed by management's commentary regarding the summary judgment decision in favor of Anchen. Shares of the Mississauga, Ont.-based specialty pharmaceutical company were up 14 cents, or 0.87%, at $16.14, on volume of 1,706,300 shares versus the three-month running average of 990,453 shares. (NYSE: BVF)

Merrill maintains Qiagen at sell

Merrill Lynch analyst Erica Whittaker kept Qiagen NV at sell after the company's reported sales beat Merrill's forecast but met consensus expectations. The company had net sales $113 million, beating the analyst's estimate of $111 million. Qiagen's adjusted net income of $18 million was slightly below Merrill's $18.2 million estimate but lower than consensus of $19.7 million. Shares of the Venlo, The Netherlands-based biotechnology company were down 21 cents, or 1.41%, at $14.70, on volume of 648,692 shares versus the three-month running average of 3639,916 shares. (Nasdaq: QGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.